You are here

Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AT008000-01
Agency Tracking Number: R41AT008000
Amount: $397,926.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCCAM
Solicitation Number: PA12-089
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1540 MAIN ST, STE 218
WINDSOR, CO 80550-7915
United States
DUNS: 78524468
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ROBERT SWIFT
 (979) 227-7289
 robert@invenux.com
Business Contact
 ROBERT SWIFT
Phone: (979) 227-7289
Email: robert@invenux.com
Research Institution
 STATE UNIVERSITY OF RUTGERS
 
RUTGERS THE STATE UNIVERSITY OF NJ NEWARK 249 UNIVERSITY AVE.
NEWARK, NJ 07102-
United States

 () -
 Nonprofit college or university
Abstract

DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HIV commands vast attention from the international community, SCD is virtually invisible. In the US, those with SCD have an average mortality in their 40s and an estimated aggregate cost of medical care in excess of 1.4 billion per year. In less developed countries, 80% of children with SCD die before the age of five. The only FDA approved disease-modifying drug for usein SCD is the anti-cancer drug hydroxyurea, which has serious side effects and is only approved for use in adults. SCD results from a mutation in the -globin gene (Hb S), a variant of Hb A, the common adult hemoglobin. When deoxygenated, Hb S polymerizes, forming long polymers that deform the biconcave red blood cells (RBCs) into rigid, adherent, sickle-shaped cells. The rigid sickled RBCs are easily trapped in the microvasculature, blocking blood flow to tissues and organs with resultant ischemic tissuedamage. Best supportive therapies for SCD include folic acid for anemia, penicillin to prevent infections, pneumococcal and influenza vaccinations, pain medication, and intravenous injection of fluids. Chronic transfusion therapy can modify the course ofthe disease, but hyperviscosity, alloimmune reaction, infection, and iron overload are just a few of the complications of transfusion therapy. Bone marrow transplants can cure SCD, but the morbidity and mortality of the procedure, coupled with difficultyin finding a donor match and the cost of the procedure, leave this an uncommon treatment option. We have identified a botanical extract with potent antisickling activity. We propose to isolate the active compounds in the botanical by bio-assay guided fractionation of the botanical extract using an in vitro assay that measures sickling of human RBCs under hypoxic conditions. The active fractions will be further fractionated, the compounds in the sub-fractions identified using mass spectroscopy and NMR, andin vivo activity confirmed in 100% human Hb S transgenic mice. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This proposal supports development of a botanical to treat sickle cell disease in children. Sickle cell disease is an inherited blooddisorder that affects ovr 100,000 persons in the U.S. Those affected often have high medical costs, a poor quality of life, and early death. The development of this drug addresses a critical unmet medical to treat this disease in children.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government